Paul G. Montgomery, MD - Hematology/Oncology
Dr. Paul G. Montgomery reviews medical content for Healthwise, a nonprofit organization with a mission to help people make better health decisions. Dr. Montgomery is a medical oncologist with the Mountain States Tumor Institute at St. Luke's Regional Medical Center in Boise, Idaho. He is a Clinical Instructor for the University of Washington in Seattle.
- American Board of Internal Medicine—1988
- Subspecialty Certification in Hematology (ABIM)—1990
- Subspecialty Certification in Oncology (ABIM)—1991
- M.D.: University of Washington Medical School, Seattle, 1985
- Internal Medicine Residency: Mayo Clinic, Rochester, MN, 1985–1988
- Hematology Fellowship: Mayo Clinic, Rochester, MN, 1988–1990
- Oncology Fellowship: Mayo Clinic, Rochester, MN, 1990–1991
- Clinical Instructor in Medicine, University of Washington, Seattle, 1993–present
- Idaho Elks Rehabilitation Hospital, Boise, ID
- Saint Alphonsus Regional Medical Center, Boise, ID
- St. Luke's Regional Medical Center, Boise, ID
- Veterans Administration Medical Center, Boise, ID
- St. Luke's Magic Valley Regional Medical Center, Twin Falls, ID
- Fellow, American College of Physicians
- American Society of Clinical Oncology
- American Society of Hematology
- Kamel OW, van de Rijn M, Weiss LM, et al. (1993). Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. New England Journal of Medicine, 328(18): 1317–1321.
- Weaver CH, Bensinger WI, Applebaum FR, et al. (1994). Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplantation, 14(5): 813–819.
- Bensinger QI, Schiffman KS, Holmberg L, et al. (1997). High-dose busulfan, melphalan, thiotepa, and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. Bone Marrow Transplantation, 19(12): 1183–1189.
- Bensinger W, Applebaum F, Rowley S, et al. (1995). Factors that influence collection and engraftment of autologous peripheral-blood stem cells. Journal of Clinical Oncology, 13(10): 2547–2555.